Crossmark

Depressive symptomatology in the first-episode schizophrenia spectrum disorders OPTiMiSE trial: prevalence, correlates, symptom progression and outcomes

Crossref DOI link: https://doi.org/10.1038/s41537-025-00681-3

Published Online: 2025-11-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lopez-Morinigo, Javier-David https://orcid.org/0000-0002-4264-2664
Fraguas, David

Diaz-Caneja, Covadonga M. https://orcid.org/0000-0001-8538-3175
Galvañ, Joaquin https://orcid.org/0009-0006-6195-570X
Berger, Gregor https://orcid.org/0000-0003-2030-141X
Leucht, Stefan https://orcid.org/0000-0002-4934-4352
Rossum, Inge Winter-van

Arango, Celso https://orcid.org/0000-0003-3382-4754
Moreno, Carmen https://orcid.org/0000-0003-0541-4846
Funding

Funding for this research was provided by:

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)

European Commission (HEALTH-F2-2010-242114)
License Information

Text and Data Mining valid from 2025-11-13

Version of Record valid from 2025-11-13
More Information

Article History

Received: 18 May 2025

Accepted: 18 September 2025

First Online: 13 November 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below